Tokyo Prefecture has taken a proactive stance against the illegal sale of the diabetes drug Mounjaro (tirzepatide) on social media, directly replying to accounts offering the drug for unauthorized sale. This move signals a tightening regulatory environment for aesthetic and weight-loss products in Japan, a key market for medical aesthetics distributors and clinics. The prefecture's actions highlight the risks of off-label use and the importance of compliance for suppliers and buyers in the supply chain.
Regulatory crackdown on social media
Tokyo Prefecture's Pharmaceutical Affairs Division has been actively monitoring X (formerly Twitter) for posts offering Mounjaro for sale without proper authorization. In fiscal year 2025, the division issued 497 warnings on X regarding illegal drug transactions, with 375 of these—about three-quarters—targeting diabetes drugs like Mounjaro. The process involves external information gathering, but staff confirm each problematic post before sending a warning. If the account does not delete the post, Tokyo reports it to X for removal.
Off-label use risks and regulatory context
Mounjaro, approved in Japan for diabetes treatment, has been misused for weight loss and cosmetic purposes. The Ministry of Health, Labour and Welfare has previously warned against off-label use, citing risks such as hypoglycemia, acute pancreatitis, and gastrointestinal side effects like nausea and vomiting. Importantly, treatment for adverse effects from off-label use may not be covered under Japan's relief system for drug-induced injuries, adding liability risks for clinics and distributors.
What buyers should watch
For overseas importers and distributors of aesthetic and weight-loss products, Tokyo's direct enforcement on social media signals a zero-tolerance approach to unauthorized sales. This could lead to stricter import controls and increased scrutiny of online marketing. Buyers should ensure their suppliers comply with Japanese regulations, including proper licensing and labeling, to avoid legal repercussions. The trend also underscores the growing demand for weight-loss solutions in Japan, but only through authorized channels.
Sourcing context
Japan's medical aesthetics market is highly regulated, and this incident highlights the importance of sourcing products through legitimate distributors. For clinic buyers, using unauthorized suppliers for off-label drugs like Mounjaro could result in legal action and reputational damage. The prefecture's commitment to "continue steadily" with these warnings suggests sustained enforcement, making compliance a key factor for market entry.
Source: Read the original report | Published: May 30, 2026